Third, the impact of constructed biologic subtype remained significant for postrecurrence DFS; it was not surprising that patients with non-Rec+/HER2- breast cancer had significantly worse 5-year DFS due to their tendency to fail locoregionally and/or metastasize distantly. The gene discussed is ERBB2; the disease is breast cancer.